◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: medium Compound WATCH-LIST MEDIUM

Injectable Glutathione

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST MEDIUM

"Companion file to `glutathione.md` covering the IV / IM route specifically. For users in this archetype: WATCH-LIST. The legitimate medical case for IV GSH is narrow — A-tier in alcoholic / non-alcoholic fatty liver disease (Honda 2017), B-tier in early Parkinson's (Sechi 1996, Hauser 2009 weaker replication; intranasal has now eclipsed IV), C-tier in cosmetic skin-lightening with documented FDA safety warnings. NAC 1200 mg/day in V4 already supplies the rate-limiting cysteine substrate for endogenous GSH synthesis with cleaner BBB delivery and far better cost / safety / convenience profile. Liposomal oral (Sinha 2018) covers chronic peripheral GSH support at $30-80/month vs $50-200 per IV infusion. Verdict-confidence MEDIUM (not HIGH) because the route does have legitimate uses if hepatic stress, post-impact specialist neurology, or specific oxidative-stress states emerge — but the cosmetic skin-whitening trade-driven mass market is meaningfully unsafe at the unregulated tail and the felt 'IV cleanse' effect is largely placebo-amplified ritual. Verdict would upgrade to OPTIONAL-ADD only if: (a) NAFLD / AFLD / chronic GGT elevation with poor oral response, (b) physician-supervised functional-medicine context with sterile compounding, and (c) a credible indication beyond cosmetic. Otherwise, prefer oral liposomal or NAC."

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload (this archetype)
    WATCH-LIST

    NAC at 1200 mg/day in V4 covers the precursor pathway with cleaner BBB delivery. IV GSH does not raise brain GSH. The cost / sterility / convenience equation is unfavorable for any non-clinical indication. Verdict-confidence MEDIUM. Reconsider only if hepatic stress emerges.

  • 30-50, executive maintenance
    WATCH-LIST

    Same logic; NAC + oral liposomal cover the use case. IV GSH only if a specific hepatic or specialist indication emerges.

  • 50+, longevity-focused
    OPTIONAL-ADD

    if hepatic stress. GlyNAC + oral liposomal dominate for chronic peripheral GSH. IV reserved for hepatic indications.

  • NAFLD / AFLD / chronic GGT elevation
    STRONG-CANDIDATE

    for physician-supervised IV protocol. A-tier hepatology evidence. 600-1200 mg IV TIW x 8-12 weeks then re-test.

  • Parkinson's prodromal / family history
    NEUTRAL

    on IV (intranasal is preferred). The Sechi 1996 signal didn't fully replicate in Hauser 2009; the Mischley 2017 intranasal route has cleaner BBB delivery and stronger PD evidence.

  • Aesthetic / skin-lightening goal
    NOT-RECOMMENDED

    Real mechanism, but FDA / Philippines FDA warnings against unregulated cosmetic clinics. Oral liposomal at chronic doses is the safer aesthetic path; even then, the magnitude is modest and reverses on cessation.

  • Combat sport / MMA
    NEUTRAL

    Not WADA-banned. The endurance-adaptation-blunting concern is the same as NAC — peri-workout dosing may impair some adaptations. Less concern in mixed-modality / strength contexts. No advantage over NAC for brain protection because IV GSH doesn't cross the BBB.

  • Hepatic stress (specifically)
    STRONG-CANDIDATE

    for physician-supervised IV.

  • Cosmetic / "wellness drip" only
    NOT-RECOMMENDED

    The ritual is mostly placebo; the safety failures in unregulated clinics are real.

▸ Subjective experience (deep)

IV GSH has a distinct subjective signature that distinguishes it from oral / liposomal:

  • Acute (during / immediately post-infusion): mild flush, sulfur taste in mouth (very common), warmth, occasional mild metallic taste. Some users report a "wave" of clarity within the first hour.
  • Hours post-infusion: subjective lift / energy / mental clarity in some users — high placebo confound.
  • Days 1-3 post-infusion: brighter skin tone, less puffy / less inflamed appearance reported by many.
  • Weeks 4-12 of chronic IV protocol: measurable skin-lightening (cosmetic context), measurable hepatic enzyme improvements (NAFLD context), reduction in inflammatory biomarkers.
  • What it does NOT feel like: not a nootropic in the cognitive-enhancement sense; not a stimulant or anxiolytic; not a replacement for NAC for brain protection because IV GSH doesn't cross the BBB.

For users in this archetype: even if IV GSH were administered, expected felt effects would be peripheral (skin, mild lift, possible recovery) — not cognitive. The decision to use IV GSH is a peripheral-indication or aesthetic decision, not a brain-protection decision.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: minimal. Endogenous molecule with tightly regulated synthesis and turnover.
  • Recommended cycle: indication-driven, NOT continuous lifelong. Most therapeutic protocols are 8-12 weeks IV, then re-evaluate, then transition to oral liposomal maintenance or stop.
  • Reset protocol: N/A.
  • Stopping protocol: No taper needed; tissue GSH returns to baseline over days to weeks via normal turnover.
  • The cosmetic-protocol model of weekly IV indefinitely is medically unjustified — peripheral GSH support beyond an induction window is better served by oral liposomal at a fraction of the cost / risk.
▸ Stacking deep dive

Synergistic with

  • N-Acetyl-Cysteine (V4 — Swanson 1200 mg/day): Precursor + direct delivery. Stacking IV GSH on top of NAC is generally redundant for healthy users with intact GCL capacity — NAC alone saturates the precursor pathway. The stack makes sense only if (a) hepatic stress persists despite NAC, (b) GCL is genetically impaired, or (c) a specific aesthetic / clinical goal calls for the rapid peripheral peak only IV provides.

  • Vitamin C (V4 — CGN 500 mg oral; or IV 1-10 g): Recycles oxidized GSH back to reduced form via the GSH-ascorbate cycle. Frequently co-administered in IV nutrient drips (Myers cocktail, Riordan IV-C). Mechanistically clean.

  • Alpha-lipoic acid (ALA): Recycles GSH from GSSG and recycles vitamins C and E independently. Sometimes co-infused.

  • Selenium: Cofactor for GPx. Adequate selenium is required for GSH to function as a peroxide-neutralizing antioxidant. Dietary or supplement.

  • Glycine + cysteine substrate base (GlyNAC pattern): Optimizes endogenous synthesis in parallel with IV delivery. More relevant for chronic protocols than acute IV.

  • B vitamins (B6, B12, folate, riboflavin): Support transsulfuration and NADPH generation. Standard IV-nutrient drip co-additions.

Avoid stacking with

  • Activated charcoal (acute poisoning context): Binds GSH and precursors. Space by 2+ hours. Not relevant for chronic IV/IM use.

  • Chemotherapy (cisplatin, doxorubicin, bleomycin): GSH may protect normal tissue from chemo-induced oxidative damage but theoretical concern about reducing tumor-killing efficacy. Specialist territory; do not self-combine during oncology treatment without oncologist clearance. Some oncology protocols specifically incorporate GSH on chemo off-days; this is an oncologist decision.

  • Endurance-adaptation training peri-workout: Same ROS-blunting concern as NAC — chronic high-dose antioxidants may impair the ROS signal needed for mitochondrial biogenesis adaptation. Less concern in MMA / strength contexts, but worth flagging if peri-workout IV is being proposed.

  • Methotrexate, immunosuppressants: Theoretical interactions via cellular GSH handling and Th1/Th2 bias. Specialist-only.

  • Liposomal oral GSH (chronic): Redundant — both deliver intact GSH peripherally. Choose one based on indication: IV for acute / clinical, liposomal for chronic daily.

Neutral / safe co-administration

  • All canonical V4/V5 stack components: no known interactions with citicoline, magnesium, DHA, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C, creatine, NAC at oral doses.
  • All V5 planned additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin, l-tryptophan — no known interactions.
  • Caffeine — no interaction.
  • Most prescription drugs at supplement doses — GSH is not a CYP enzyme inducer/inhibitor.
▸ Drug interactions deep dive
  • Activated charcoal: Binds GSH; space by 2+ hours.
  • Chemotherapy agents: Theoretical reduction in tumor-killing oxidative stress. Specialist territory.
  • Methotrexate: Theoretical interaction via cellular GSH handling.
  • Immunosuppressants: GSH supports cellular immunity; theoretical opposition. Monitor in transplant / autoimmune contexts.
  • Nitrates: No direct interaction documented for GSH (vs. NAC, which does interact). Lower concern.
  • CYP enzymes: Not a notable inducer or inhibitor at supplement doses.
  • Sulfa drugs: No direct interaction. The sulfur in GSH is structurally different from sulfonamide drugs; cross-reactivity is not documented.
▸ Pharmacogenomics
  • GCLC, GCLM (glutamate-cysteine ligase subunits): Encode the rate-limiting enzyme in GSH synthesis. GCLM -588 C/T carriers may benefit more from IV/exogenous delivery (which bypasses synthesis) than from NAC alone.
  • GSTM1, GSTT1, GSTP1 null variants: Reduce GSH-conjugation capacity. Carriers theoretically benefit more from GSH supplementation generally; IV's advantage over oral is delivery speed, not capacity restoration.
  • GGT1 polymorphisms: Affect plasma GSH half-life via GGT activity. High-GGT genotypes clear plasma GSH faster, reducing the benefit window of a single IV push.
  • CDO1, CTH: Affect cysteine catabolism partitioning. Less directly relevant to IV GSH than to NAC.
  • 23andMe relevance for users in this archetype (results ~June 2026): Worth checking GCLM -588, GCLC variants, GSTM1, GSTT1, GSTP1, GGT1. None will likely flip the WATCH-LIST verdict on IV GSH unless a strong low-capacity profile emerges combined with a hepatic indication.
▸ Sourcing deep dive

This is a regulated injectable with significant supply-chain heterogeneity. Sourcing options:

Path Form Vendor Cost Reliability Notes
Compounding (US) IV / IM vials Wellness Pharmacy, Hopewell, College Pharmacy, AnazaoHealth, Empower Pharmacy $40-100 per vial (varies) high Requires Rx from a willing physician. 503A patient-specific or 503B outsourcing. USP <797> sterile preparation standards. The reliable path.
Functional medicine clinic IV push or drip IV-nutrient / wellness clinics across US $50-200 per infusion varies Quality varies — choose physician-supervised settings; verify sterile compounding source.
Specialty hepatology / neurology IV protocol Hospital outpatient, specialty physician practices Variable, sometimes insurance-covered high Highest reliability for legitimate medical indications.
Cosmetic IV-clinic (US) IV drip Wellness / "drip bar" chains $100-300 per session varies Often co-infused with vitamin C and B-complex; verify sourcing.
Cosmetic IV-clinic (Asia) IV / IM Philippines, Thailand, India, Vietnam, Indonesia $20-80 per session LOW — FDA-warned Avoid. Documented contamination, sterility failures, anaphylaxis, SJS/TEN, content variability. The Philippines FDA has issued multiple advisories.
Black market / online Vials Illicit channels $20-60 per vial Very low Avoid. Sterility, identity, and dose accuracy all unverified.

Recommended for users in this archetype: do NOT add IV GSH today. V4 NAC + V5 oral liposomal-GSH-if-needed handles the precursor + peripheral pathways at $0-80/month. IV GSH is a clinical-indication tool, not a wellness-routine tool.

If a specific indication emerges (hepatic stress confirmed on labs, specialist neurology decision):

  • US 503A / 503B compounding pharmacy with Rx is the only acceptable path.
  • Verify the prescribing physician understands the specific indication and has chosen IV over oral / liposomal / NAC for a documented mechanistic reason.
▸ Biomarkers to track (deep)

  • Baseline (before starting):

    • Liver panel: ALT, AST, GGT (especially GGT — most sensitive marker of hepatocyte oxidative stress)
    • hsCRP
    • Whole-blood GSH or RBC GSH (specialty labs — Doctor's Data, Genova, Quest specialty panel)
    • GSH/GSSG ratio (the canonical redox indicator; specialty labs)
    • 8-OHdG (DNA oxidative damage; specialty labs)
    • F2-isoprostanes (lipid peroxidation; specialty labs)
    • MDA (malondialdehyde; specialty labs)
    • Plasma cysteine
    • Oxidized LDL
    • Skin melanin index (if cosmetic context — usually clinical visual assessment + melanin-meter)

  • During use (every 4-12 weeks during active IV protocol):

    • Liver panel (GGT, ALT, AST) — primary endpoint for hepatic indications
    • hsCRP — inflammatory burden
    • GSH (RBC if accessible)
    • GSH/GSSG ratio
    • 8-OHdG, F2-isoprostanes
    • Subjective: post-infusion energy / clarity; skin appearance

  • Post-protocol (after IV cycle ends):

    • Liver panel + hsCRP at 4 weeks post to confirm durability
    • Decision: transition to oral liposomal maintenance or stop

For users in this archetype: the June 2026 baseline panel is the trigger event. If standard liver panel is normal, IV GSH has no current indication.

▸ Controversies / open debates Live debate

Is the Sechi 1996 IV-PD signal real?

Partial. The original n=9 open-label study showed striking ~42% UPDRS improvement, but Hauser 2009 randomized pilot (n=21) showed only modest, non-significant improvement. The mechanism (peripheral antioxidant support + theoretical rim-zone access) is biochemically plausible, but the BBB-crossing problem limits what IV can do for nigrostriatal neurons. Modern specialist preference is intranasal (Mischley 2017) for direct CNS delivery. IV is C-tier for PD now in clinical practice; specialty / functional-medicine settings still use it.

Does IV GSH raise brain GSH?

No, not meaningfully. Intact GSH does not cross the BBB. The plasma peak is dramatic; brain levels barely move. This is the central practical fact about IV GSH and the reason the "IV detox / brain optimization" marketing is overstated.

Is the cosmetic skin-lightening effect real?

Yes, mechanism + small-trial data confirm it. Tyrosinase inhibition + eumelanin → pheomelanin shift is documented. Sotiriou 2019 systematic review and Sonthalia 2016 trials confirm measurable melanin index reduction at 6-12 weeks. But the safety failures in unregulated cosmetic clinics are equally real — anaphylaxis, SJS/TEN, sterility issues, content variability. The FDA, Philippines FDA, and multiple national regulators have issued specific warnings. The effect is also transient and reverses on cessation. Net: a real pharmacologic effect that is unsafe to access through the dominant supply chain.

Is plasma half-life ~10 minutes a problem?

No, clinically. Tissue uptake (especially liver and erythrocytes) is fast enough that the redox-state shift persists much longer than plasma kinetics suggest. Clinical protocols rely on repeated dosing 1-3x weekly rather than continuous infusion. The PK detail matters for rate-of-administration (slow push reduces transient anaphylactoid risk) but doesn't undermine the therapeutic rationale.

Is IV GSH safer than oral liposomal?

Generally no, given equivalent indications. Sterile compounding minimizes risk in clinic settings, but oral liposomal has zero injection-site / sterility / contamination risk, costs 5-10× less, and matches IV on chronic peripheral GSH endpoints (Sinha 2018). IV's advantage is specifically the rapid peripheral peak — relevant for acute clinical indications, not chronic wellness use.

Is the FDA warning specifically about cosmetic use, or all IV GSH?

Primarily cosmetic. The FDA enforcement actions and consumer advisories specifically target compounded GSH marketed for skin-lightening, addressing both safety failures (anaphylaxis, SJS/TEN, contamination) and the absence of FDA approval for cosmetic indication. Therapeutic IV GSH at physician-supervised functional-medicine clinics with sterile compounding falls in regulatory gray space — it is not FDA-approved for any IV indication, but the enforcement focus has been on cosmetic abuse rather than off-label therapeutic use.

Will the Mischley 2017 intranasal protocol replace IV GSH for PD?

Likely, in specialty practice. Intranasal addresses the BBB-crossing problem, has cleaner CNS delivery, and the Mischley 2017 RCT has stronger evidence than the historical Sechi/Hauser IV trials. Replication trials 2024-2026 have been positive but smaller. For the user, irrelevant — not a current indication.

Where does IV GSH sit in the GSH-delivery hierarchy?

Full ranked hierarchy of practical options for raising GSH (efficacy + practicality combined):

For brain GSH:

  1. NAC (cheap, daily-safe, BBB-penetrant) — the user's V stack default.
  2. NACET (best brain delivery on paper; sourcing-bottlenecked).
  3. Intranasal GSH (Mischley protocol; only direct-GSH route with credible CNS evidence).
  4. GlyNAC (NAC + glycine) (better than NAC alone for older / depleted populations).
  5. S-acetyl glutathione (modest BBB penetration).
  6. Liposomal GSH (peripheral only).
  7. Plain oral GSH (essentially null).
  8. IV / IM GSH (peripheral only; does NOT raise brain GSH).

For peripheral / hepatic / immune GSH:

  1. IV GSH (gold-standard rapid peripheral peak; clinical indications).
  2. IM GSH (slower than IV; less common).
  3. Liposomal oral GSH (practical OTC chronic alternative).
  4. NAC (cheaper precursor; equivalent for many endpoints).
  5. S-acetyl glutathione (peripheral + modest BBB).
  6. Plain oral GSH (poorly absorbed).

For users in this archetype: brain protection is the priority; NAC dominates the hierarchy. IV GSH is irrelevant for the current indication set.

▸ Verdict change log
  • 2026-05-10 — Initial deep-research route-specific verdict for IV/IM glutathione: WATCH-LIST (MEDIUM confidence). Companion to glutathione.md master file. For the user: V4 NAC 1200 mg/day handles the rate-limiting cysteine substrate with cleaner BBB delivery and dramatically better cost / safety / convenience. IV GSH has narrow legitimate indications (A-tier hepatology, B-tier specialist Parkinson's increasingly displaced by intranasal, C-tier cosmetic skin-lightening with FDA safety warnings). Reserve for: (a) confirmed hepatic stress on bloodwork, (b) physician-supervised functional-medicine indication, (c) specialist neurology context. Avoid cosmetic skin-whitening clinics, especially in unregulated international markets.
▸ Open questions / gaps Open

  1. Will the June 2026 bloodwork show any hepatic-stress signal warranting IV protocol consideration? ALT, AST, GGT are standard panel items. Specialty oxidative-stress markers (8-OHdG, F2-isoprostanes) usually require add-on.

  2. Is there a clean RCT of IV GSH in active combat-sport athletes for subconcussive impact biomarker improvement? No — and the BBB-crossing problem makes this unlikely to ever be a strong indication. NAC remains the brain-relevant route.

  3. How safe is therapeutic IV GSH at physician-supervised US 503A/503B compounding settings over 5+ years of intermittent use? Limited prospective safety data beyond 12-week trial windows. Hepatology long-term experience suggests good safety; cosmetic-clinic horror stories don't generalize to sterile-compounded therapeutic use.

  4. Will FDA take broader enforcement action against non-cosmetic compounded IV GSH? Possible — the regulatory environment around 503A compounding has been tightening. Sourcing reliability could shift in the next 2-3 years.

  5. Does IV GSH offer any peripheral-compartment advantage over chronic oral liposomal at equivalent cost-equivalent doses? The Sinha 2018 RBC/PBMC data suggest oral liposomal can match IV on chronic endpoints; the unique IV advantage is rapid peripheral peak (acute indications) and direct hepatic uptake (NAFLD/AFLD).

  6. Is the "skin-whitening drip" market trending up or down across Asia in 2024-2026? Anecdotally still strong despite regulatory warnings; the cosmetic demand exceeds the regulatory enforcement bandwidth.

References

Witschi et al. 1992 — The systemic availability of oral glutathione (Eur J Clin Pharmacol) — PMID 1505142

pubmed.ncbi.nlm.nih.gov · 1992
View Study

Allen & Bradley 2011 — Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers — PMID 21982056

pubmed.ncbi.nlm.nih.gov · 2011
View Study

Park et al. 2014 — Oral and IV pharmacokinetic comparison of glutathione — PMID 24993685

pubmed.ncbi.nlm.nih.gov · 2014
View Study

Honda et al. 2017 — Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study (BMC Gastroenterol) — PMID 28838403

pubmed.ncbi.nlm.nih.gov · 2017

landmark NAFLD pilot

View Study

Sechi et al. 1996 — Reduced intravenous glutathione in the treatment of early Parkinson's disease (Prog Neuropsychopharmacol Biol Psychiatry) — PMID 8866716

pubmed.ncbi.nlm.nih.gov · 1996

landmark IV PD trial

View Study

FDA — Compounded Drug Products Not Intended To Be Used For Skin Lightening

fda.gov

FDA enforcement and consumer advisory page

View Source

Philippines FDA Advisory No. 2019-172 — Unregistered IV glutathione products

fda.gov.ph · 2019

regulatory advisory documenting safety concerns

View Source

Philippines FDA — Position paper on glutathione IV for skin whitening (multiple advisories 2010s-2020s)

fda.gov.ph

multiple Philippines FDA advisories

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…